Biopharmeceutical company Pfizer Inc. is teaming up with the German BioNTech SE to conduct an early-stage study to analyze a vaccination capable of protecting individuals against COVID-19 and influenza.
The companies announced on Thursday that the single-dose vaccine candidate would be made up of the Omicron booster shot and the mRNA flu shot produced by Pfizer.
The study will evaluate whether the shot is tolerable, as well as safer, for human patients or if it has the ability to produce a response by the immune system. One hundred-eighty human participants from the U.S. between the ages of 18 and 64 will be used in the study,
